
Alessandro Serretti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9270708/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mindfulness-Based Stress Reduction for Stress Management in Healthy People: A Review and Meta-Analysis. Journal of Alternative and Complementary Medicine, 2009, 15, 593-600.	2.1	1,232
2	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	9.4	1,191
3	Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clinical Psychology Review, 2011, 31, 449-464.	6.0	946
4	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	13.5	935
5	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	9.4	629
6	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	4.0	579
7	A systematic review of neurobiological and clinical features of mindfulness meditations. Psychological Medicine, 2010, 40, 1239-1252.	2.7	533
8	Mindfulness based cognitive therapy for psychiatric disorders: A systematic review and meta-analysis. Psychiatry Research, 2011, 187, 441-453.	1.7	518
9	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry, 2007, 12, 247-257.	4.1	487
10	Antidepressants and Body Weight. Journal of Clinical Psychiatry, 2010, 71, 1259-1272.	1.1	480
11	Treatment-Emergent Sexual Dysfunction Related to Antidepressants. Journal of Clinical Psychopharmacology, 2009, 29, 259-266.	0.7	455
12	Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder. Journal of Clinical Psychiatry, 2007, 68, 1062-1070.	1.1	407
13	Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry, 2010, 15, 473-500.	4.1	405
14	The role of specific early trauma in adult depression: A meta-analysis of published literature. Childhood trauma and adult depression. European Psychiatry, 2015, 30, 665-680.	0.1	393
15	Mindfulness: Top–down or bottom–up emotion regulation strategy?. Clinical Psychology Review, 2013, 33, 82-96.	6.0	328
16	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. European Neuropsychopharmacology, 2012, 22, 239-258.	0.3	283
17	Mindfulness-Based Interventions for Chronic Pain: A Systematic Review of the Evidence. Journal of Alternative and Complementary Medicine, 2011, 17, 83-93.	2.1	281
18	Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. American Journal of Medical Genetics Part A 2003, 123B, 23-26	2.4	272

#	Article	IF	CITATIONS
19	Are Mindfulness-Based Interventions Effective for Substance Use Disorders? A Systematic Review of the Evidence. Substance Use and Misuse, 2014, 49, 492-512.	0.7	262
20	Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Molecular Psychiatry, 2018, 23, 133-142.	4.1	247
21	Genetic dissection of psychopathological symptoms: Insomnia in mood disorders andCLOCK gene polymorphism. American Journal of Medical Genetics Part A, 2003, 121B, 35-38.	2.4	228
22	Social brain, social dysfunction and social withdrawal. Neuroscience and Biobehavioral Reviews, 2019, 97, 10-33.	2.9	216
23	Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression. Journal of Clinical Psychiatry, 2000, 61, 26-29.	1.1	216
24	Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression. Biological Psychiatry, 2001, 50, 323-330.	0.7	213
25	Serotonin Transporter Gene Variants and Behavior: A Comprehensive Review. Current Drug Targets, 2006, 7, 1659-1669.	1.0	190
26	A glycogen synthase kinase 3-β promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neuroscience Letters, 2004, 368, 123-126.	1.0	189
27	Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-β â°'50 T/C SNP. Neuroscience Letters, 2005, 376, 51-55.	1.0	184
28	Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 631-635.	1.1	179
29	Depressive symptomatology is influenced by chronotypes. Journal of Affective Disorders, 2009, 119, 100-106.	2.0	179
30	Paroxetine for the treatment of depression: a critical update. Expert Opinion on Pharmacotherapy, 2012, 13, 421-431.	0.9	176
31	The genetics of bipolar disorder: genome †`hot regions,' genes, new potential candidates and future directions. Molecular Psychiatry, 2008, 13, 742-771.	4.1	175
32	Pharmacogenetics in major depression: A comprehensive meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 183-194.	2.5	174
33	Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular Psychiatry, 2001, 6, 586-592.	4.1	169
34	Personality and attempted suicide. Analysis of anger, aggression and impulsivity. Journal of Psychiatric Research, 2009, 43, 1262-1271.	1.5	167
35	A single nucleotide polymorphism in glycogen synthase kinase 3-β promoter gene influences onset of illness in patients affected by bipolar disorder. Neuroscience Letters, 2004, 355, 37-40.	1.0	156
36	Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Molecular Psychiatry, 2001, 6, 579-585.	4.1	150

#	Article	IF	CITATIONS
37	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. American Journal of Psychiatry, 2015, 172, 617-629.	4.0	150
38	Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research, 1998, 32, 255-259.	1.5	148
39	A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. International Clinical Psychopharmacology, 2011, 26, 130-140.	0.9	148
40	Insomnia improvement during antidepressant treatment andCLOCK gene polymorphism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 36-39.	1.1	146
41	Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. Psychiatry Research, 2016, 240, 421-430.	1.7	145
42	Influence of a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene on the Effects of Total Sleep Deprivation in Bipolar Depression. American Journal of Psychiatry, 1999, 156, 1450-1452.	4.0	145
43	Pharmacogenetics of antidepressant response. Journal of Psychiatry and Neuroscience, 2011, 36, 87-113.	1.4	144
44	Gene environment interaction studies in depression and suicidal behavior: An update. Neuroscience and Biobehavioral Reviews, 2013, 37, 2375-2397.	2.9	143
45	HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies. Current Medicinal Chemistry, 2007, 14, 2053-2069.	1.2	138
46	Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Research, 2012, 198, 74-80.	1.7	138
47	Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Molecular Psychiatry, 2005, 10, 598-605.	4.1	134
48	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. Journal of Psychiatric Research, 2011, 45, 309-321.	1.5	133
49	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 398-404.	2.5	126
50	Clozapine resistance: Augmentation strategies. European Neuropsychopharmacology, 2012, 22, 165-182.	0.3	121
51	The C(–1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. International Journal of Neuropsychopharmacology, 2004, 7, 453-460.	1.0	119
52	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	0.7	114
53	Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. International Journal of Neuropsychopharmacology, 2007, 10, 437.	1.0	111
54	European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings. European Neuropsychopharmacology, 2012, 22, 453-468.	0.3	111

#	Article	IF	CITATIONS
55	Serotonergic genes and suicide: A systematic review. European Neuropsychopharmacology, 2013, 23, 1125-1142.	0.3	109
56	Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics Journal, 2001, 1, 71-77.	0.9	107
57	Possible association between ???G308A tumour necrosis factor-?? gene polymorphism and major depressive disorder in the Korean population. Psychiatric Genetics, 2003, 13, 179-181.	0.6	107
58	The association between electrodermal activity (EDA), depression and suicidal behaviour: A systematic review and narrative synthesis. BMC Psychiatry, 2018, 18, 22.	1.1	107
59	The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1074-1084.	2.5	104
60	Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. European Neuropsychopharmacology, 2001, 11, 375-380.	0.3	103
61	New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects. Current Medicinal Chemistry, 2004, 11, 343-358.	1.2	102
62	Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients. Psychiatry Research, 2012, 200, 389-394.	1.7	96
63	The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 105-118.	1.8	96
64	The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Clinical Psychopharmacology, 2008, 23, 1-8.	0.9	95
65	Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Molecular Psychiatry, 1999, 4, 280-283.	4.1	94
66	Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychological Medicine, 2010, 40, 187-200.	2.7	94
67	Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. Journal of Affective Disorders, 2006, 90, 251-256.	2.0	93
68	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology, 2019, 29, 971-985.	0.3	93
69	Social adjustment and self-esteem of bipolar patients: a multicentric study. Journal of Affective Disorders, 2004, 79, 97-103.	2.0	92
70	Genetics of Alzheimer's Disease. A Rapidly Evolving Field. Journal of Alzheimer's Disease, 2007, 12, 73-92.	1.2	92
71	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatrica Scandinavica, 2019, 139, 78-88.	2.2	92
72	Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. International Journal of Neuropsychopharmacology, 2002, 5, 27-35.	1.0	91

#	Article	IF	CITATIONS
73	Effect of 5â€HT1A gene polymorphisms on antidepressant response in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 115-123.	1.1	89
74	Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. World Journal of Biological Psychiatry, 2019, 20, 427-448.	1.3	89
75	SSRIs antidepressant activity is influenced by Gβ3 variants. European Neuropsychopharmacology, 2003, 13, 117-122.	0.3	88
76	Occurrence of Cognitive Impairment and Dementia after the Age of 60: A Population-Based Study from Northern Italy. Dementia and Geriatric Cognitive Disorders, 2005, 19, 97-105.	0.7	88
77	The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. Neuroscience and Biobehavioral Reviews, 2013, 37, 1597-1610.	2.9	88
78	Psychological Mechanisms of Mindfulness-Based Interventions. Holistic Nursing Practice, 2014, 28, 124-148.	0.3	88
79	Profiles of "manic―symptoms in bipolar I, bipolar II and major depressive disorders. Journal of Affective Disorders, 2005, 84, 159-166.	2.0	85
80	Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Biological Psychiatry, 2003, 54, 687-692.	0.7	83
81	Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2011, 31, 512-516.	0.7	83
82	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. American Journal of Psychiatry, 2020, 177, 76-92.	4.0	83
83	Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders11This work was partially supported by the BIOMED 2 grant BMH4-CT97-2307 Journal of Psychiatric Research, 1999, 33, 371-377.	1.5	82
84	The 5â€HTTLPR Polymorphism and Posttraumatic Stress Disorder: A Metaâ€Analysis. Journal of Traumatic Stress, 2013, 26, 645-653.	1.0	82
85	Psychometric characteristic of the Italian version of the Temperament and Character Inventory—Revised, personality, psychopathology, and attachment styles. Comprehensive Psychiatry, 2008, 49, 514-522.	1.5	81
86	Serotonin transporter gene (5-HTTLPR) and major psychoses. Molecular Psychiatry, 2002, 7, 95-99.	4.1	79
87	Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. European Journal of Human Genetics, 2004, 12, 377-382.	1.4	78
88	Genetic modulation of personality traits. International Clinical Psychopharmacology, 2014, 29, 1-15.	0.9	78
89	Sexual Side Effects of Pharmacological Treatment of Psychiatric Diseases. Clinical Pharmacology and Therapeutics, 2011, 89, 142-147.	2.3	77
90	The 5â€HTTLPR polymorphism and eating disorders: A metaâ€analysis. International Journal of Eating Disorders, 2011, 44, 191-199.	2.1	77

#	Article	IF	CITATIONS
91	Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 487-520.	1.1	77
92	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. European Neuropsychopharmacology, 2015, 25, 441-453.	0.3	77
93	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. Journal of Psychiatric Research, 2017, 91, 1-13.	1.5	77
94	Gene–environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. Psychiatry Research, 2003, 119, 99-111.	1.7	76
95	Refining Prediction in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2018, 79, 16m11385.	1.1	76
96	Temperament and Character in Mood Disorders: Influence of DRD4, SERTPR, TPH and MAO-A Polymorphisms. Neuropsychobiology, 2006, 53, 9-16.	0.9	75
97	Antidepressants in elderly: Metaregression of double-blind, randomized clinical trials. Journal of Affective Disorders, 2013, 147, 1-8.	2.0	75
98	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World Journal of Biological Psychiatry, 2017, 18, 5-28.	1.3	75
99	Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics Journal, 2008, 8, 90-100.	0.9	74
100	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. Journal of Affective Disorders, 2016, 189, 224-232.	2.0	73
101	A New Prediction Model for Evaluating Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2017, 78, 215-222.	1.1	73
102	Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenetics and Genomics, 2005, 15, 61-67.	0.7	72
103	Pharmacogenetics of Antidepressants. Frontiers in Pharmacology, 2011, 2, 6.	1.6	72
104	Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug and Alcohol Dependence, 1994, 36, 139-145.	1.6	71
105	HTR2C andHTR1A gene variants in German and Italian suicide attempters and completers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 291-299.	1.1	70
106	Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. Journal of Affective Disorders, 2009, 115, 27-35.	2.0	70
107	Shared genetics among major psychiatric disorders. Lancet, The, 2013, 381, 1339-1341.	6.3	70
108	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. International Clinical Psychopharmacology, 2009, 24, 250-256.	0.9	69

#	Article	IF	CITATIONS
109	Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications. Current Psychiatry Reports, 2015, 17, 50.	2.1	69
110	Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects. Biomedicine and Pharmacotherapy, 2009, 63, 228-235.	2.5	67
111	The influence of childhood trauma on the onset and repetition of suicidal behavior: An investigation in a high risk sample of male prisoners. Journal of Psychiatric Research, 2011, 45, 742-747.	1.5	67
112	Dopamine receptor D2 and D4 genes, GABAA alpha-1 subunit gene and response to lithium prophylaxis in mood disorders. Psychiatry Research, 1999, 87, 7-19.	1.7	66
113	Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. Journal of Psychiatric Research, 2000, 34, 89-98.	1.5	66
114	Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. Biological Psychiatry, 2001, 49, 405-409.	0.7	66
115	The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics Journal, 2004, 4, 233-244.	0.9	66
116	Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American Journal of Medical Genetics Part A, 2004, 129B, 36-40.	2.4	66
117	Aripiprazole in the Treatment of Depressive and Anxiety Disorders. CNS Drugs, 2008, 22, 367-388.	2.7	66
118	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. Molecular Psychiatry, 2021, 26, 3363-3373.	4.1	66
119	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1101-1115.	1.5	64
120	Temperament and character of suicide attempters. Journal of Psychiatric Research, 2008, 42, 938-945.	1.5	63
121	A quantitative approach to neuropsychiatry: The why and the how. Neuroscience and Biobehavioral Reviews, 2019, 97, 3-9.	2.9	63
122	The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Progress in Neurobiology, 2011, 94, 418-460.	2.8	61
123	Identification of symptomatologic patterns common to major psychoses: Proposal for a phenotype definition. , 1996, 67, 393-400.		60
124	Symptomatologic analysis of psychotic and non-psychotic depression. Journal of Affective Disorders, 1999, 54, 183-187.	2.0	60
125	DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: A study on 2,011 affected subjects. American Journal of Medical Genetics Part A, 2001, 105, 283-290.	2.4	60
126	Depressive syndrome in major psychoses: a study on 1351 subjects. Psychiatry Research, 2004, 127, 85-99.	1.7	60

#	Article	IF	CITATIONS
127	Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Molecular Psychiatry, 2000, 5, 270-274.	4.1	57
128	Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders. American Journal of Medical Genetics Part A, 2002, 114, 361-369.	2.4	57
129	Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opinion on Pharmacotherapy, 2009, 10, 1561-1570.	0.9	57
130	Dimensions of major psychoses: a confirmatory factor analysis of six competing models. Psychiatry Research, 2004, 127, 101-109.	1.7	56
131	5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. International Journal of Neuropsychopharmacology, 2008, 11, 701-21.	1.0	56
132	The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. Clinical Psychopharmacology and Neuroscience, 2018, 16, 1-6.	0.9	56
133	Mode of inheritance in mood disorder families according to fluvoxamine response. Acta Psychiatrica Scandinavica, 1998, 98, 443-450.	2.2	55
134	Clinical and demographic features of mood disorder subtypes. Psychiatry Research, 2002, 112, 195-210.	1.7	55
135	Pharmacogenetics in affective disorders. European Journal of Pharmacology, 2002, 438, 117-128.	1.7	55
136	Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics Journal, 2004, 4, 267-273.	0.9	55
137	How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. European Neuropsychopharmacology, 2007, 17, 587-594.	0.3	55
138	No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Research, 2001, 104, 195-203.	1.7	54
139	Focus on HTR2C: A possible suggestion for genetic studies of complex disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 601-637.	1.1	54
140	Antidepressants in healthy subjects: What are the psychotropic/psychological effects?. European Neuropsychopharmacology, 2010, 20, 433-453.	0.3	54
141	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. Psychiatry Research, 2015, 226, 474-483.	1.7	54
142	Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis. European Neuropsychopharmacology, 2016, 26, 163-185.	0.3	54
143	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). International Journal of Neuropsychopharmacology, 2018, 21, 539-549.	1.0	54
144	Genetics of resilience: Implications from genomeâ€wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 77-94.	1.1	54

#	Article	IF	CITATIONS
145	Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. , 1998, 81, 127-130.		53
146	Safety and Tolerability of Lamotrigine. Clinical Neuropharmacology, 2011, 34, 39-47.	0.2	53
147	Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. Neuropsychobiology, 2012, 65, 1-11.	0.9	53
148	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 174-186.	1.4	53
149	Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110266.	2.5	53
150	Evidence for an Association between the Dopamine D3 Receptor Gene DRD3 and Schizophrenia. Human Heredity, 1997, 47, 6-16.	0.4	52
151	From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology, 2004, 174, 490-503.	1.5	52
152	5-HTTLPR and gender differences in affective disorders: A systematic review. Journal of Affective Disorders, 2016, 190, 193-207.	2.0	52
153	Excess of allele1 for α3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Molecular Psychiatry, 2002, 7, 201-207.	4.1	51
154	Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology, 2013, 227, 509-519.	1.5	51
155	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders. American Journal of Medical Genetics Part A, 2002, 114, 177-185.	2.4	50
156	Pharmacogenetics of lithium prophylaxis in mood disorders: Analysis of COMT, MAO-A, and G?3 variants. American Journal of Medical Genetics Part A, 2002, 114, 370-379.	2.4	50
157	NOS-I and -III gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 42-48.	1.1	50
158	The use of the defence style questionnaire in major depressive and panic disorders: A comprehensive metaâ€analysis. Psychology and Psychotherapy: Theory, Research and Practice, 2010, 83, 1-13.	1.3	50
159	Newer antidepressants and panic disorder. International Clinical Psychopharmacology, 2013, 28, 33-45.	0.9	50
160	Cognitive markers of psychotic unipolar depression: A meta-analytic study. Journal of Affective Disorders, 2015, 174, 580-588.	2.0	50
161	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. European Neuropsychopharmacology, 2016, 26, 1960-1971.	0.3	50
162	Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression. Journal of Affective Disorders, 1999, 56, 17-25.	2.0	49

#	Article	IF	CITATIONS
163	Neural network analysis in pharmacogenetics of mood disorders. BMC Medical Genetics, 2004, 5, 27.	2.1	49
164	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. European Neuropsychopharmacology, 2009, 19, 562-570.	0.3	49
165	Mindfulness-Based Cognitive Therapy Versus Psycho-Education for Patients with Major Depression Who Did Not Achieve Remission Following Antidepressant Treatment: A Preliminary Analysis. Journal of Alternative and Complementary Medicine, 2012, 18, 756-760.	2.1	49
166	A meta-analysis of cognitive performance in melancholic versus non-melancholic unipolar depression. Journal of Affective Disorders, 2016, 201, 15-24.	2.0	49
167	Tryptophan hydroxylase gene and major psychoses. Psychiatry Research, 2001, 103, 79-86.	1.7	48
168	The 5-HT2C receptor as a target for mood disorders. Expert Opinion on Therapeutic Targets, 2004, 8, 15-23.	1.5	48
169	Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatric Genetics, 2006, 16, 153-158.	0.6	48
170	Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics. World Journal of Biological Psychiatry, 2017, 18, 492-505.	1.3	48
171	Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. American Journal of Medical Genetics Part A, 2002, 114, 380-390.	2.4	47
172	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2015, 64, 88-98.	1.5	47
173	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). European Neuropsychopharmacology, 2018, 28, 752-760.	0.3	47
174	Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 809-815.	1.1	46
175	From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment. Canadian Journal of Psychiatry, 2014, 59, 62-75.	0.9	46
176	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. Frontiers in Pharmacology, 2020, 11, 575540.	1.6	46
177	Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. International Journal of Neuropsychopharmacology, 1998, 1, 125-129.	1.0	45
178	Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. International Journal of Neuropsychopharmacology, 2004, 7, 489-493.	1.0	45
179	Serotonin transporter gene influences the time course of improvement of "core―depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Research, 2007, 149, 185-193.	1.7	45
180	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. Journal of Affective Disorders, 2011, 128, 56-63.	2.0	45

#	Article	IF	CITATIONS
181	Escitalopram plasma levels and antidepressant response. European Neuropsychopharmacology, 2017, 27, 940-944.	0.3	45
182	Acute antipyschotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1562-1566.	2.5	44
183	Quetiapine XR: Current status for the treatment of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1165-1173.	2.5	44
184	Genetic modulation of borderline personality disorder: Systematic review and meta-analysis. Journal of Psychiatric Research, 2013, 47, 1275-1287.	1.5	44
185	Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression. Journal of Clinical Psychopharmacology, 2015, 35, 296-303.	0.7	44
186	Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. Journal of Affective Disorders, 2015, 179, 88-94.	2.0	44
187	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry, 2019, 214, 36-41.	1.7	44
188	Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. Depression and Anxiety, 2006, 23, 389-397.	2.0	43
189	Genetics of Late-Onset Alzheimer's Disease: Update from the Alzgene Database and Analysis of Shared Pathways. International Journal of Alzheimer's Disease, 2011, 2011, 1-14.	1.1	43
190	A protective genetic variant for adverse environments? The role of childhood traumas and serotonin transporter gene on resilience and depressive severity in a high-risk population. European Psychiatry, 2011, 26, 471-478.	0.1	43
191	Factor analysis of delusional disorder symptomatology. Comprehensive Psychiatry, 1999, 40, 143-147.	1.5	42
192	Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology, 2004, 174, 504-11.	1.5	42
193	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. Journal of Psychiatric Research, 2009, 43, 519-525.	1.5	42
194	Interaction between SERTPR and stressful life events on response to antidepressant treatment. European Neuropsychopharmacology, 2009, 19, 64-67.	0.3	42
195	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. International Clinical Psychopharmacology, 2009, 24, 1-18.	0.9	42
196	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Research, 2011, 189, 26-32.	1.7	42
197	Clinical, psychological and environmental predictors of prospective suicide events in patients with Bipolar Disorder. Journal of Psychiatric Research, 2013, 47, 1800-1808.	1.5	42
198	Dopamine receptor D2 Ser/Cys311 variant associated with disorganized symptomatology of schizophrenia. Schizophrenia Research, 1998, 34, 207-210.	1.1	41

#	Article	IF	CITATIONS
199	European Collaborative Project on Affective Disorders. Psychiatric Genetics, 1998, 8, 197-205.	0.6	41
200	Serotonin transporter gene and adverse life events in adult ADHD. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1461-1469.	1.1	41
201	Association between GSK-3β -50T/C polymorphism and personality and psychotic symptoms in mood disorders. Psychiatry Research, 2008, 158, 132-140.	1.7	41
202	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics Journal, 2014, 14, 463-472.	0.9	41
203	Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. Journal of Psychiatric Research, 2001, 35, 217-223.	1.5	40
204	Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 239-244.	1.8	40
205	Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. World Journal of Biological Psychiatry, 2011, 12, 364-375.	1.3	40
206	Quetiapine for bipolar depression. International Clinical Psychopharmacology, 2012, 27, 76-90.	0.9	40
207	Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. Journal of Affective Disorders, 2009, 119, 205-209.	2.0	39
208	Vitamin B12 Levels in Alzheimer's Disease: Association with Clinical Features and Cytokine Production. Journal of Alzheimer's Disease, 2010, 19, 481-488.	1.2	39
209	Genetics of long-term treatment outcome in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 65, 17-24.	2.5	39
210	Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 36-44.	2.5	39
211	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. International Clinical Psychopharmacology, 1996, 11, 109-17.	0.9	39
212	Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders. Translational Psychiatry, 2022, 12, 59.	2.4	39
213	A European multicenter association study ofHTR2A receptor polymorphism in bipolar affective disorder. , 2000, 96, 136-140.		38
214	Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 193-198.	1.8	38
215	The <i>CLOCK</i> Gene and Mood Disorders: A Case-Control Study and Meta-analysis. Chronobiology International, 2011, 28, 825-833.	0.9	38
216	Mechanisms of antidepressant action: An integrated dopaminergic perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1532-1543.	2.5	38

#	Article	IF	CITATIONS
217	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder — A European Multicenter Study. European Neuropsychopharmacology, 2012, 22, 259-266.	0.3	38
218	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 271-278.	2.5	38
219	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. Journal of Affective Disorders, 2015, 184, 51-59.	2.0	38
220	Role of 108 schizophreniaâ€associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 757-764.	1.1	38
221	Social adjustment and self-esteem in remitted patients with mood disorders. European Psychiatry, 1999, 14, 137-142.	0.1	37
222	<i>Ban</i> I Polymorphism of the Cytosolic Phospholipase A ₂ Gene and Mood Disorders in the Korean Population. Neuropsychobiology, 2004, 49, 185-188.	0.9	37
223	Heat-shock protein-70 genes and response to antidepressants in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1006-1011.	2.5	37
224	Pharmacogenetics of antidepressant response: An update. Human Genomics, 2008, 3, 257.	1.4	37
225	A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World Journal of Biological Psychiatry, 2011, 12, 501-515.	1.3	37
226	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatrica Scandinavica, 2018, 137, 401-412.	2.2	37
227	A Glutamate Transporter EAAT1 Gene Variant Influences Amygdala Functional Connectivity in Bipolar Disorder. Journal of Molecular Neuroscience, 2018, 65, 536-545.	1.1	37
228	White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress. Molecular Neurobiology, 2019, 56, 702-710.	1.9	37
229	Dopamine receptor D4 gene is associated with delusional symptomatology in mood disorders. Psychiatry Research, 1998, 80, 129-136.	1.7	36
230	Factor Analysis of Mania. Archives of General Psychiatry, 1999, 56, 671.	13.8	36
231	Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Research, 2004, 125, 65-68.	1.7	36
232	Functional neural correlates of mindfulness meditations in comparison with psychotherapy, pharmacotherapy and placebo effect. Is there a link?. Acta Neuropsychiatrica, 2010, 22, 104-117.	1.0	36
233	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110170.	2.5	36
234	MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 387-392.	2.5	35

#	Article	IF	CITATIONS
235	Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 36, 147-154.	2.5	35
236	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 375-387.	2.5	35
237	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	0.9	35
238	Analysis of depressive symptomatology in mood disorders. Depression and Anxiety, 1998, 8, 80-85.	2.0	34
239	Genetic Variants of Dopamine Receptor D4 and Psychopathology. Schizophrenia Bulletin, 1999, 25, 609-618.	2.3	34
240	Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. Neuroscience Research, 2005, 53, 8-13.	1.0	34
241	<i>3111T/C CLOCK</i> GENE POLYMORPHISM IS NOT ASSOCIATED WITH SLEEP DISTURBANCES IN UNTREATED DEPRESSED PATIENTS. Chronobiology International, 2010, 27, 265-277.	0.9	34
242	Depression across mood disorders: review and analysis in a clinical sample. Comprehensive Psychiatry, 2012, 53, 24-38.	1.5	34
243	Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics Journal, 2015, 15, 538-548.	0.9	34
244	Newâ€generation, nonâ€5SRI antidepressants: Drugâ€drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Medicinal Research Reviews, 2020, 40, 1794-1832.	5.0	34
245	Clinical and demographic features of psychotic and nonpsychotic depression. Comprehensive Psychiatry, 1999, 40, 358-362.	1.5	33
246	Serotonin transporter gene is not associated with symptomatology of schizophrenia. Schizophrenia Research, 1999, 35, 33-39.	1.1	33
247	Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Research, 2004, 127, 279-281.	1.7	33
248	Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression. Journal of Clinical Psychopharmacology, 2005, 25, 471-475.	0.7	33
249	Pooling pharmacogenetic studies on the serotonin transporter: A mega-analysis. Psychiatry Research, 2006, 145, 61-65.	1.7	33
250	Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: An exploratory analysis. Psychiatry and Clinical Neurosciences, 2006, 60, 598-604.	1.0	33
251	HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study. Molecular Psychiatry, 2007, 12, 797-798.	4.1	33
252	APOE epsilonâ€4 allele and cytokine production in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 338-344.	1.3	33

#	Article	IF	CITATIONS
253	The 3111T/C Polymorphism Interacts With Stressful Life Events to Influence Patterns of Sleep in Females. Chronobiology International, 2012, 29, 891-897.	0.9	33
254	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Translational Psychiatry, 2020, 10, 50.	2.4	33
255	5-HT2A SNPs and the Temperament and Character Inventory. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1275-1281.	2.5	32
256	COMT and age at onset in mood disorders: A replication and extension study. Neuroscience Letters, 2011, 498, 218-221.	1.0	32
257	The role of serotonergic genes and environmental stress on the development of depressive symptoms and neuroticism. Journal of Affective Disorders, 2012, 142, 82-89.	2.0	32
258	MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 393-403.	1.8	32
259	Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naĂ ⁻ ve patients with first major depression episode. Journal of Psychiatric Research, 2013, 47, 162-167.	1.5	32
260	Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. International Journal of Neuropsychopharmacology, 2014, 17, 1-8.	1.0	32
261	Clinical and genetic factors associated with suicide in mood disorder patients. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 181-193.	1.8	32
262	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. Journal of Affective Disorders, 2018, 227, 777-786.	2.0	32
263	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. International Journal of Neuropsychopharmacology, 2019, 22, 93-104.	1.0	32
264	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 99, 109835.	2.5	32
265	Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Research, 2000, 94, 185-190.	1.7	31
266	Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 751-757.	2.5	31
267	Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatric Genetics, 2004, 14, 147-150.	0.6	31
268	Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 199-205.	1.8	31
269	Neuroticism, social network, stressful life events: Association with mood disorders, depressive symptoms and suicidal ideation in a community sample of women. Psychiatry Research, 2015, 226, 38-44.	1.7	31
270	Clinical factors related to schizophrenia relapse. International Journal of Psychiatry in Clinical Practice, 2016, 20, 54-69.	1.2	31

#	Article	IF	CITATIONS
271	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 203-210.	2.5	31
272	Pharmacogenetics in Psychiatry. Advances in Pharmacology, 2018, 83, 297-331.	1.2	31
273	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	1.0	31
274	Pharmacogenetics of selective serotonin reuptake inhibitor response. Pharmacogenetics and Genomics, 2004, 14, 607-613.	5.7	30
275	Genes involved in Alzheimer's disease, a survey of possible candidates. Journal of Alzheimer's Disease, 2005, 7, 331-353.	1.2	30
276	HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. European Journal of Clinical Pharmacology, 2010, 66, 5-27.	0.8	30
277	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 305-311.	1.8	30
278	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. Journal of Neural Transmission, 2013, 120, 1709-1715.	1.4	30
279	TPH1, MAOA, Serotonin Receptor 2A and 2C Genes in Citalopram Response: Possible Effect in Melancholic and Psychotic Depression. Neuropsychobiology, 2013, 67, 41-47.	0.9	30
280	Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1157-1168.	1.5	30
281	Bipolar II disorder as a risk factor for postpartum depression. Journal of Affective Disorders, 2016, 204, 54-58.	2.0	30
282	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	4.1	30
283	Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. Psychiatric Genetics, 2006, 16, 181-182.	0.6	29
284	No Association of TPH1 218A/C Polymorphism with Treatment Response and Intolerance to SSRIs in Japanese Patients with Major Depression. Neuropsychobiology, 2007, 56, 167-171.	0.9	29
285	Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 701-703.	1.1	29
286	Antidepressant response and intolerance to SSRI is not influenced by G-protein β3 subunit gene C825T polymorphism in Japanese major depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1041-1044.	2.5	29
287	Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. Journal of Affective Disorders, 2011, 135, 241-250.	2.0	29
288	Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: A principal component analysis of lifetime pharmacological and biophysic treatment options. European Neuropsychopharmacology, 2013, 23, 263-275.	0.3	29

#	Article	IF	CITATIONS
289	Family history of a mood disorder indicates a more severe bipolar disorder. Journal of Affective Disorders, 2014, 156, 178-186.	2.0	29
290	Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics. Neuropsychobiology, 2015, 71, 218-224.	0.9	29
291	Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation. Psychiatry Research, 1999, 89, 107-114.	1.7	28
292	Linkage of mood disorders with D2, D3 and TH genes: a multicenter study. Journal of Affective Disorders, 2000, 58, 51-61.	2.0	28
293	Components of self-esteem in affective patients and non-psychiatric controls. Journal of Affective Disorders, 2005, 88, 93-98.	2.0	28
294	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. European Neuropsychopharmacology, 2013, 23, 895-901.	0.3	28
295	Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. Pharmacogenetics and Genomics, 2014, 24, 314-319.	0.7	28
296	The association of personality trait on treatment outcomes in patients with chronic prostatitis/chronic pelvic pain syndrome: An exploratory study. Journal of Psychosomatic Research, 2014, 76, 127-133.	1.2	28
297	Genetic Variability in CYP2E1 and Catalase Gene Among Currently and Formerly Alcohol-Dependent Male Subjects. Alcohol and Alcoholism, 2015, 50, 140-145.	0.9	28
298	Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis. Molecular Neurobiology, 2016, 53, 2065-2081.	1.9	28
299	Psychotic Features in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	28
300	Impact of clinical variables on illness time course in mood disorders. Psychiatry Research, 2000, 97, 217-227.	1.7	27
301	Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population. Psychiatry and Clinical Neurosciences, 2003, 57, 399-403.	1.0	27
302	Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenetics and Genomics, 2007, 17, 69-75.	0.7	27
303	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. European Neuropsychopharmacology, 2013, 23, 887-894.	0.3	27
304	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. Journal of Psychiatric Research, 2014, 56, 72-81.	1.5	27
305	Cariprazine specificity profile in the treatment of acute schizophrenia. International Clinical Psychopharmacology, 2017, 32, 309-318.	0.9	27
306	Temperament and character influence on depression treatment outcome. Journal of Affective Disorders, 2019, 252, 464-474.	2.0	27

#	Article	IF	CITATIONS
307	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. Neuropsychopharmacology, 2021, 46, 1821-1829.	2.8	27
308	Predicting Response to Lithium in Mood Disorders. Molecular Diagnosis and Therapy, 2003, 3, 17-30.	3.3	26
309	Comparison of Response to Fluvoxamine in Nondemented Elderly Compared to Younger Patients Affected by Major Depression. Journal of Clinical Psychopharmacology, 2003, 23, 535-539.	0.7	26
310	Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatric Genetics, 2003, 13, 121-126.	0.6	26
311	5-HT1A polymorphism and self-transcendence in mood disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 33-35.	1.1	26
312	The Impact of Heat Shock Protein 70 Gene Variations on Clinical Presentation and Outcome in Schizophrenic Inpatients. Neuropsychobiology, 2009, 59, 135-141.	0.9	26
313	Early antidepressant efficacy modulation by glutamatergic gene variants in the STARâŽD. European Neuropsychopharmacology, 2013, 23, 612-621.	0.3	26
314	Clinical features and drug induced side effects in early versus late antidepressant responders. Journal of Psychiatric Research, 2013, 47, 1309-1318.	1.5	26
315	Predictors of switch from depression to mania in bipolar disorder. Journal of Psychiatric Research, 2015, 66-67, 45-53.	1.5	26
316	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv125.	1.0	26
317	Genetics of Serotonin Receptors and Depression: State of the Art. Current Drug Targets, 2013, 14, 531-548.	1.0	26
318	Incomplete Coverage of Candidate Genes: A Poorly Considered Bias. Current Genomics, 2007, 8, 476-483.	0.7	25
319	Lithium Pharmacodynamics and Pharmacogenetics: Focus on Inositol Mono Phosphatase (IMPase), Inositol Poliphosphatase (IPPase) and Glycogen Sinthase Kinase 3 Beta (CSK-3 Beta). Current Medicinal Chemistry, 2009, 16, 1917-1948.	1.2	25
320	5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry Research, 2009, 167, 97-105.	1.7	25
321	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. Journal of Psychiatric Research, 2010, 44, 598-604.	1.5	25
322	Precision psychiatry in clinical practice. International Journal of Psychiatry in Clinical Practice, 2021, 25, 19-27.	1.2	25
323	Dopamine receptorD4 gene is not associated with major psychoses. , 1999, 88, 486-491.		24
324	Serotonin transporter gene not associated with psychotic symptomatology of mood disorders. Psychiatry Research, 1999, 86, 59-65.	1.7	24

#	Article	IF	CITATIONS
325	Clinical prediction of antidepressant response in mood disorders: Linear multivariate vs. neural network models. Psychiatry Research, 2007, 152, 223-231.	1.7	24
326	The serotonin transporter gene and effectiveness of SSRIs. Expert Review of Neurotherapeutics, 2008, 8, 111-120.	1.4	24
327	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. European Neuropsychopharmacology, 2009, 19, 718-725.	0.3	24
328	Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenetics and Genomics, 2009, 19, 121-128.	0.7	24
329	Lack of Association between Interleukin-1 alpha rs1800587 Polymorphism and Alzheimer's Disease in Two Independent European Samples. Journal of Alzheimer's Disease, 2009, 16, 181-187.	1.2	24
330	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 93-103.	1.8	24
331	Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls. Psychiatry Research, 2015, 228, 945-949.	1.7	24
332	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry, 2016, 16, 106.	1.1	24
333	Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 703-717.	1.8	24
334	Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. Psychiatry Research, 2003, 118, 241-247.	1.7	23
335	Dopamine transporter haplotype and attention-deficit hyperactivity disorder. Molecular Psychiatry, 2005, 10, 617-618.	4.1	23
336	Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre. BMC Psychiatry, 2006, 6, 11.	1.1	23
337	Dysbindin gene (DTNBP1) and schizophrenia in Korean population. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 137-142.	1.8	23
338	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. Journal of Psychiatric Research, 2010, 44, 487-492.	1.5	23
339	T3111C CLOCK SINGLE NUCLEOTIDE POLYMORPHISM AND MOOD DISORDERS: A META-ANALYSIS. Chronobiology International, 2010, 27, 706-721.	0.9	23
340	Specificity profile of paroxetine in major depressive disorder: Meta-regression of double-blind, randomized clinical trials. Journal of Affective Disorders, 2011, 132, 14-25.	2.0	23
341	Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Research, 2012, 198, 39-46.	1.7	23
342	Trait-aggressiveness and impulsivity: Role of psychological resilience and childhood trauma in a sample of male prisoners. Nordic Journal of Psychiatry, 2014, 68, 8-17.	0.7	23

#	Article	IF	CITATIONS
343	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. Neuropsychobiology, 2016, 74, 159-168.	0.9	23
344	Expansion and further delineation of the <i>SETD5</i> phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance. Clinical Genetics, 2018, 93, 752-761.	1.0	23
345	Duloxetine plasma level and antidepressant response. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 127-132.	2.5	23
346	Clutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenetics and Genomics, 2011, 21, 206-216.	0.7	23
347	Serum Testosterone Concentration in Combat-Related Chronic Posttraumatic Stress Disorder. Neuropsychobiology, 2012, 65, 90-95.	0.9	23
348	Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. Clinical Psychopharmacology and Neuroscience, 2020, 18, 1-9.	0.9	23
349	GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. Psychiatric Genetics, 1998, 8, 251-254.	0.6	22
350	Rapid cycling mood disorder: Clinical and demographic features. Comprehensive Psychiatry, 2002, 43, 336-343.	1.5	22
351	Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 519-523.	2.5	22
352	Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case???control study. Psychiatric Genetics, 2003, 13, 211-220.	0.6	22
353	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. Neuropsychobiology, 2012, 65, 70-75.	0.9	22
354	Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings. CNS and Neurological Disorders - Drug Targets, 2012, 11, 299-305.	0.8	22
355	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. Psychiatry Research, 2013, 209, 121-123.	1.7	22
356	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. Journal of Clinical Psychopharmacology, 2015, 35, 220-227.	0.7	22
357	CHL1,ITGB3andSLC6A4gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. Pharmacogenomics, 2015, 16, 689-701.	0.6	22
358	Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. Neuroscience and Biobehavioral Reviews, 2019, 97, 47-69.	2.9	22
359	Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. International Clinical Psychopharmacology, 2020, 35, 233-242.	0.9	22
360	The socio-economical burden of schizophrenia: A simulation of cost-offset of early intervention program in Italy. European Psychiatry, 2009, 24, 11-16.	0.1	21

#	Article	IF	CITATIONS
361	Self-Harm in Prisoners. CNS Spectrums, 2011, 16, 75-81.	0.7	21
362	Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. Journal of Affective Disorders, 2012, 141, 72-78.	2.0	21
363	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. Neuroscience Letters, 2012, 516, 85-88.	1.0	21
364	CACNA1C gene and schizophrenia. Psychiatric Genetics, 2015, 25, 163-167.	0.6	21
365	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. Neuropsychobiology, 2016, 73, 35-42.	0.9	21
366	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 723-735.	1.8	21
367	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110050.	2.5	21
368	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. , 2000, 96, 84-87.		20
369	Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study. European Neuropsychopharmacology, 2003, 13, 365-368.	0.3	20
370	Antidepressant response in the elderly. Psychiatry Research, 2007, 152, 37-44.	1.7	20
371	Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines. Neuropsychobiology, 2011, 63, 1-7.	0.9	20
372	A molecular pathway analysis informs the genetic background at risk for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 59, 21-30.	2.5	20
373	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational Psychiatry, 2015, 5, e513-e513.	2.4	20
374	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109638.	2.5	20
375	No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. Psychiatry Investigation, 2013, 10, 180.	0.7	20
376	Serotonin-2C and serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders. , 2000, 96, 161-166.		19
377	Influence of postpartum onset on the course of mood disorders. BMC Psychiatry, 2006, 6, 4.	1.1	19
378	A neural network model for combining clinical predictors of antidepressant response in mood disorders. Journal of Affective Disorders, 2007, 98, 239-245.	2.0	19

#	Article	IF	CITATIONS
379	Thyroid hormones affect recovery from depression during antidepressant treatment. Psychiatry and Clinical Neurosciences, 2009, 63, 305-313.	1.0	19
380	TAAR6 variations possibly associated with antidepressant response and suicidal behavior. Psychiatry Research, 2010, 180, 20-24.	1.7	19
381	The genetics of antipsychotic induced tremors: A genomeâ€wide pathway analysis on the STEPâ€BD SCP sample. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 975-986.	1.1	19
382	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. Journal of Psychopharmacology, 2013, 27, 616-628.	2.0	19
383	Serious suicidal behaviors: Socio-demographic and clinical features in a multinational, multicenter sample. Nordic Journal of Psychiatry, 2014, 68, 44-52.	0.7	19
384	Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. Molecular Diagnosis and Therapy, 2014, 18, 567-577.	1.6	19
385	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. International Journal of Psychiatry in Clinical Practice, 2014, 18, 97-102.	1.2	19
386	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study. International Clinical Psychopharmacology, 2016, 31, 1-7.	0.9	19
387	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International Clinical Psychopharmacology, 2017, 32, 235-248.	0.9	19
388	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. European Neuropsychopharmacology, 2017, 27, 625-632.	0.3	19
389	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2022, 55, 86-95.	0.3	19
390	Tyrosine hydroxylase gene in linkage disequilibrium with mood disorders. Molecular Psychiatry, 1998, 3, 169-174.	4.1	18
391	No interaction of GABAA alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. , 1999, 88, 44-49.		18
392	Melancholic features and response to lithium prophylaxis in mood disorders. Depression and Anxiety, 2000, 11, 73-79.	2.0	18
393	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. International Clinical Psychopharmacology, 2010, 25, 297-301.	0.9	18
394	Role of Substance Abuse Comorbidity and Personality on the Outcome of Depression in Bipolar Disorder: Harm Avoidance Influences Medium-Term Treatment Outcome. Psychopathology, 2012, 45, 174-178.	1.1	18
395	Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. European Neuropsychopharmacology, 2019, 29, 777-785.	0.3	18
396	Genetic underpinnings of sociability in the general population. Neuropsychopharmacology, 2021, 46, 1627-1634.	2.8	18

#	Article	IF	CITATIONS
397	Sexâ€related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. Depression and Anxiety, 2021, 38, 896-906.	2.0	18
398	Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: A multicenter association study. , 1999, 88, 527-532.		17
399	Effect of reboxetine augmentation in SSRI resistant patients. , 2000, 15, 143-145.		17
400	Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. Psychiatry and Clinical Neurosciences, 2003, 57, 153-159.	1.0	17
401	TNFB polymorphism may be associated with schizophrenia in the Korean population. Schizophrenia Research, 2003, 61, 39-45.	1.1	17
402	Polymorphism of the Serotonin Transporter Gene and Symptomatic Dimensions of Schizophrenia in the Korean Population. Neuropsychobiology, 2003, 47, 182-186.	0.9	17
403	Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: The role of clinical, psychosocial and genetic variables. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 442-448.	2.5	17
404	Further evidence of MAO-A gene variants associated with bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 37-40.	1.1	17
405	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 757-761.	1.1	17
406	Neuro-imaging of mindfulness meditations: implications for clinical practice. Epidemiology and Psychiatric Sciences, 2011, 20, 205-210.	1.8	17
407	Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability. Journal of Affective Disorders, 2013, 148, 316-322.	2.0	17
408	Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia. OMICS A Journal of Integrative Biology, 2016, 20, 283-289.	1.0	17
409	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of Psychiatric Research, 2017, 89, 97-104.	1.5	17
410	Predominant polarity in bipolar disorder patients: The COPE bipolar sample. Journal of Affective Disorders, 2019, 250, 43-50.	2.0	17
411	Personalized and precision medicine as informants for treatment management of bipolar disorder. International Clinical Psychopharmacology, 2019, 34, 189-205.	0.9	17
412	Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature. Human Molecular Genetics, 2019, 28, 972-979.	1.4	17
413	Melancholic features in major depression – a European multicenter study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110285.	2.5	17
414	Pharmacogenetics and Depression: A Critical Perspective. Psychiatry Investigation, 2019, 16, 645-653.	0.7	17

#	Article	IF	CITATIONS
415	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. American Journal of Medical Genetics Part A, 1999, 88, 294-297.	2.4	16
416	Two new rare variants in the circadian "clock―gene may influence sleep pattern. Genetics in Medicine, 2005, 7, 455-457.	1.1	16
417	Cognitive Status, Depressive Symptoms, and Health Status as Predictors of Functional Disability Among Elderly Persons With Low-to-Moderate Education: The Faenza Community Aging Study. American Journal of Geriatric Psychiatry, 2005, 13, 672-685.	0.6	16
418	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 308-315.	1.1	16
419	Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 375-379.	2.5	16
420	Association between the estrogen receptor TA polymorphism and Harm avoidance. Neuroscience Letters, 2009, 467, 155-158.	1.0	16
421	Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance. Journal of Psychopharmacology, 2010, 24, 1747-1754.	2.0	16
422	Is cognitive behavioural therapy an effective complement to antidepressants in adolescents? A meta-analysis. Acta Neuropsychiatrica, 2011, 23, 263-271.	1.0	16
423	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 65-74.	1.8	16
424	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 385-391.	1.8	16
425	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry, 2016, 16, 172.	1.1	16
426	Depression, antidepressants, and insulin resistance: which link?. European Neuropsychopharmacology, 2022, 60, 4-6.	0.3	16
427	Interaction between the Tryptophan Hydroxylase Gene and the Serotonin Transporter Gene in Schizophrenia but Not in Bipolar or Unipolar Affective Disorders. Neuropsychobiology, 2005, 51, 3-9.	0.9	15
428	DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. Neuroscience Letters, 2008, 440, 150-154.	1.0	15
429	TAAR 6 and HSP-70 variations associated with bipolar disorder. Neuroscience Letters, 2009, 465, 257-261.	1.0	15
430	Investigation of an epistastic effect between a set of TAAR6 and HSPâ€70 genes variations and major mood disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 680-683.	1.1	15
431	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. Neuroscience Letters, 2012, 506, 170-174.	1.0	15
432	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. Journal of Affective Disorders, 2014, 168, 91-97.	2.0	15

#	Article	IF	CITATIONS
433	Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder. Pharmacogenetics and Genomics, 2015, 25, 354-362.	0.7	15
434	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. World Journal of Biological Psychiatry, 2015, 16, 472-482.	1.3	15
435	Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. Neuropsychobiology, 2016, 74, 1-7.	0.9	15
436	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Advances in Therapy, 2017, 34, 713-724.	1.3	15
437	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. European Neuropsychopharmacology, 2018, 28, 1305-1313.	0.3	15
438	Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. Psychiatry Investigation, 2016, 13, 247.	0.7	15
439	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. Clinical Psychopharmacology and Neuroscience, 2015, 13, 48-52.	0.9	15
440	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. International Clinical Psychopharmacology, 1996, 11, 109-117.	0.9	14
441	Dopamine D3 receptor gene not associated with symptomatology of major psychoses. , 1999, 88, 476-480.		14
442	No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders. Psychiatry Research, 1999, 86, 203-209.	1.7	14
443	Seasonal variations of lithium plasma levels. Psychiatry Research, 2002, 111, 35-41.	1.7	14
444	Monocyte chemoattractant protein-1 promoter –2518 polymorphism and schizophrenia in the Korean population. Psychiatric Genetics, 2004, 14, 65-67.	0.6	14
445	No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia. Neuroscience Research, 2005, 52, 195-199.	1.0	14
446	Interaction analysis between 5-HTTLPR and TNFA â^'238/â^'308 polymorphisms in schizophrenia. Journal of Neural Transmission, 2006, 113, 887-897.	1.4	14
447	Estrogen receptor gene 1 variants are not associated with suicidal behavior. Psychiatry Research, 2008, 160, 1-7.	1.7	14
448	<i>TAAR6</i> variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study. European Psychiatry, 2008, 23, 390-395.	0.1	14
449	Antipsychotic Response in the First Week Predicts Later Efficacy. Neuropsychobiology, 2012, 66, 100-105.	0.9	14
450	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. Journal of Affective Disorders, 2013, 150, 649-652.	2.0	14

#	Article	IF	CITATIONS
451	Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1093-1118.	1.5	14
452	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. Journal of Neural Transmission, 2015, 122, 43-58.	1.4	14
453	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. Advances in Therapy, 2018, 35, 1656-1670.	1.3	14
454	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14
455	Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. Neuroscience Letters, 2020, 726, 133651.	1.0	14
456	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. European Neuropsychopharmacology, 2020, 41, 70-80.	0.3	14
457	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. Journal of Psychiatric Research, 2021, 141, 167-175.	1.5	14
458	How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. Clinical Psychopharmacology and Neuroscience, 2020, 18, 484-492.	0.9	14
459	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 715-727.	1.8	14
460	Lithium long-term treatment in mood disorders: clinical and genetic predictors. Pharmacogenomics, 2002, 3, 117-129.	0.6	13
461	Predictors of Early Worsening after Switch to Aripiprazole. Clinical Drug Investigation, 2010, 30, 187-193.	1.1	13
462	Factors associated with the course of symptoms in bipolar disorder during a 1-year follow-up: Depression vs. sub-threshold mixed state. Nordic Journal of Psychiatry, 2011, 65, 419-426.	0.7	13
463	Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis. Current Alzheimer Research, 2012, 9, 491-499.	0.7	13
464	Effects of antipsychotic drugs on insight in schizophrenia. Psychiatry Research, 2014, 218, 20-24.	1.7	13
465	The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades. Journal of Affective Disorders, 2016, 190, 429-438.	2.0	13
466	Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 23-29.	2.5	13
467	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. Neuropsychobiology, 2019, 77, 67-72.	0.9	13
468	Cortico-limbic functional connectivity mediates the effect of early life stress on suicidality in bipolar depressed 5-HTTLPR*s carriers. Journal of Affective Disorders, 2020, 263, 420-427.	2.0	13

#	Article	IF	CITATIONS
469	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. Psychiatry Investigation, 2014, 11, 481.	0.7	13
470	Ethical problems in pharmacogenetic studies of psychiatric disorders. Pharmacogenomics Journal, 2006, 6, 289-295.	0.9	12
471	Pharmacogenetics of Lithium Long-Term Treatment: Focus on Initiation and Adaptation Mechanisms. Neuropsychobiology, 2010, 62, 61-71.	0.9	12
472	NCAM1, TACR1 and NOS Genes and Temperament: A Study on Suicide Attempters and Controls. Neuropsychobiology, 2011, 64, 32-37.	0.9	12
473	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. Journal of Clinical Psychopharmacology, 2013, 33, 131-132.	0.7	12
474	HSP70 polymorphisms in first psychotic episode drug-naÃ⁻ve schizophrenic patients. Life Sciences, 2014, 100, 133-137.	2.0	12
475	Alcohol Dependence and Genetic Variability in the Serotonin Pathway among Currently and Formerly Alcohol-Dependent Males. Neuropsychobiology, 2015, 72, 57-64.	0.9	12
476	Genetic variability in tryptophan hydroxylase 2 gene in alcohol dependence and alcohol-related psychopathological symptoms. Neuroscience Letters, 2015, 604, 86-90.	1.0	12
477	Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. Journal of the Neurological Sciences, 2016, 370, 162-166.	0.3	12
478	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, 2019, 249, 410-417.	2.0	12
479	Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines. Current Alzheimer Research, 2013, 10, 154-164.	0.7	12
480	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C, CHRNA7</i> and <i>MAPK1</i> . Clinical Psychopharmacology and Neuroscience, 2019, 17, 364-368.	0.9	12
481	No interaction between serotonin transporter gene and dopamine receptorD4 gene in symptomatology of major psychoses. , 1999, 88, 481-485.		11
482	Social adjustment could be associated with the serotonin transporter gene in remitted patients with mood disorders and healthy subjects. Psychiatry Research, 2005, 134, 191-194.	1.7	11
483	Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. European Neuropsychopharmacology, 2009, 19, 806-811.	0.3	11
484	Sociodemographic Features Predict Antidepressant Trajectories of Response in Diverse Antidepressant Pharmacotreatment Environments. Journal of Clinical Psychopharmacology, 2011, 31, 345-348.	0.7	11
485	Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STARâŽD) trial. European Neuropsychopharmacology, 2013, 23, 1739-1746.	0.3	11
486	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. Human Psychopharmacology, 2014, 29, 388-391.	0.7	11

#	Article	IF	CITATIONS
487	Influence of differentially expressed genes from suicide post-mortem study on personality traits as endophenotypes on healthy subjects and suicide attempters. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 423-432.	1.8	11
488	The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia. International Journal of Molecular Sciences, 2015, 16, 2517-2529.	1.8	11
489	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. Neuropsychobiology, 2016, 73, 160-168.	0.9	11
490	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 ls Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 27-31.	0.7	11
491	Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. Neuropsychobiology, 2017, 76, 209-221.	0.9	11
492	Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder. Journal of Affective Disorders, 2020, 261, 181-186.	2.0	11
493	Pharmacogeneticâ€Guided Treatment of Depression: Realâ€World Clinical Applications, Challenges, and Perspectives. Clinical Pharmacology and Therapeutics, 2021, 110, 573-581.	2.3	11
494	Genetics and pharmacogenetics of mood disorders. Psychiatria Polska, 2017, 51, 197-203.	0.2	11
495	Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. Neuroscience Letters, 2006, 406, 107-112.	1.0	10
496	Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. Annals of General Psychiatry, 2007, 6, 5.	1.2	10
497	Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 Variations Does Not Impact Alcohol Dependence Disorder Features. International Journal of Environmental Research and Public Health, 2009, 6, 1980-1990.	1.2	10
498	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 434-438.	1.1	10
499	TPH2 gene variants and anxiety during alcohol detoxification outcome. Psychiatry Research, 2009, 167, 106-114.	1.7	10
500	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. Psychiatry Research, 2010, 179, 222-225.	1.7	10
501	Clinical and Demographic Predictors of Improvement during Duloxetine Treatment in Patients with Major Depression. Clinical Drug Investigation, 2011, 31, 385-405.	1.1	10
502	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. Psychiatry Research, 2011, 188, 166-169.	1.7	10
503	Generalized tonic–clonic seizure secondary to duloxetine poisoning: A short report with favorable out come. NeuroToxicology, 2012, 33, 189-190.	1.4	10
504	The Impact of Adverse Life Events on Clinical Features and Interaction with Gene Variants in Mood Disorder Patients. Psychopathology, 2013, 46, 384-389.	1.1	10

#	Article	IF	CITATIONS
505	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 482-490.	1.2	10
506	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. International Journal of Neuropsychopharmacology, 2017, 20, 782-787.	1.0	10
507	CRY1 Variations Impacts on the Depressive Relapse Rate in a Sample of Bipolar Patients. Psychiatry Investigation, 2015, 12, 118.	0.7	10
508	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. American Journal of Medical Genetics Part A, 2002, 114, 177-85.	2.4	10
509	Persistence of suicidal ideation within acute phase treatment of major depressive disorder: analysis of clinical predictors. International Clinical Psychopharmacology, 2022, 37, 193-200.	0.9	10
510	Metabolic side effects of second generation antipsychotic agents in antipsychotic-naÃ ⁻ ve patients: One-month prospective evaluation. Psychiatry Research, 2008, 157, 269-271.	1.7	9
511	Schizophrenia: genetics, prevention and rehabilitation. Acta Neuropsychiatrica, 2009, 21, 109-120.	1.0	9
512	Influence of TAAR6 polymorphisms on response to aripiprazole. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 822-826.	2.5	9
513	Excessive daytime sleepiness in depressed women. Psychiatry Research, 2010, 179, 171-175.	1.7	9
514	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. Psychiatry Research, 2010, 178, 430-432.	1.7	9
515	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. Neuroscience Letters, 2012, 508, 37-41.	1.0	9
516	Pharmacogenetics of antidepressants and mood stabilizers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 715-744.	1.0	9
517	Personalized therapies in psychiatry: promises, pitfalls and perspectives. Journal of Neural Transmission, 2015, 122, 1-3.	1.4	9
518	Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. Neuropsychobiology, 2019, 78, 79-85.	0.9	9
519	Genetic variants associated with psychotic symptoms across psychiatric disorders. Neuroscience Letters, 2020, 720, 134754.	1.0	9
520	Seasonality in Major Depressive Disorder: Effect of Sex and Age. Journal of Affective Disorders, 2022, 296, 111-116.	2.0	9
521	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. International Clinical Psychopharmacology, 2022, 37, 38-45.	0.9	9
522	Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank. Psychological Medicine, 2023, 53, 3000-3008.	2.7	9

#	Article	IF	CITATIONS
523	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. European Neuropsychopharmacology, 2022, 60, 91-99.	0.3	9
524	The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?. International Clinical Psychopharmacology, 2022, 37, 263-275.	0.9	9
525	Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Human Psychopharmacology, 2004, 19, 25-29.	0.7	8
526	Case–control association study ofGRIA1,GRIA2andGRIA4polymorphisms in bipolar disorder. International Journal of Psychiatry in Clinical Practice, 2012, 16, 18-26.	1.2	8
527	Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia. Genetic Testing and Molecular Biomarkers, 2013, 17, 504-507.	0.3	8
528	Family history of major depression and residual symptoms in responder and non-responder depressed patients. Comprehensive Psychiatry, 2014, 55, 51-55.	1.5	8
529	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. Psychiatry Research, 2014, 215, 799-800.	1.7	8
530	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. Neuropsychobiology, 2015, 72, 118-125.	0.9	8
531	High occupational level is associated with poor response to treatment of depression. European Neuropsychopharmacology, 2016, 26, 1320-1326.	0.3	8
532	The brief assessment of cognition in affective disorders: Normative data for the Italian population. Journal of Affective Disorders, 2019, 252, 245-252.	2.0	8
533	Opinion paper: poor response to treatment of depression in people in high occupational levels. Psychological Medicine, 2019, 49, 49-54.	2.7	8
534	Quantitative neurosymptomatics: Linking quantitative biology to neuropsychiatry. Neuroscience and Biobehavioral Reviews, 2019, 97, 1-2.	2.9	8
535	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 901-910.	1.8	8
536	The black sheep of the family- whole-exome sequencing in family of lithium response discordant bipolar monozygotic twins. European Neuropsychopharmacology, 2020, 34, 19-27.	0.3	8
537	Further evidence supporting the association between the dopamine receptor D2 Ser/Cys311 variant and disorganized symptomatology of schizophrenia. Schizophrenia Research, 2000, 43, 161-2.	1.1	8
538	Polygenic risk scores for neuropsychiatric, inflammatory, and cardioâ€metabolic traits highlight possible genetic overlap with suicide attempt and treatmentâ€emergent suicidal ideation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2022, 189, 74-85.	1.1	8
539	The Influence of 5-HTTLPR, BDNF Rs6265 and COMT Rs4680 Polymorphisms on Impulsivity in Bipolar Disorder: The Role of Gender. Genes, 2022, 13, 482.	1.0	8
540	"Separation" of the mother-child couple: pregnancy and maternity of drug-dependent women. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 47-53.	0.7	7

#	Article	IF	CITATIONS
541	Self-esteem in remitted patients with mood disorders is not associated with the dopamine receptor D4 and the serotonin transporter genes. Psychiatry Research, 1998, 80, 137-144.	1.7	7
542	VNTR Polymorphism of Tyrosine Hydroxylase Gene and Schizophrenia in the Korean Population. Neuropsychobiology, 2003, 47, 131-136.	0.9	7
543	Personality and Genetics. Current Psychiatry Reviews, 2007, 3, 147-159.	0.9	7
544	Depression and Social Phobia Secondary to Alcohol Dependence. Neuropsychobiology, 2007, 56, 111-118.	0.9	7
545	Tyrosine Hydroxylase and DOPA Decarboxylase Gene Variants in Personality Traits. Neuropsychobiology, 2009, 59, 23-27.	0.9	7
546	Further evidence supporting the association between 5HTR2C gene and bipolar disorder. Psychiatry Research, 2010, 180, 151-152.	1.7	7
547	No association between genetic markers inBDNFgene and lithium prophylaxis in a Greek sample. International Journal of Psychiatry in Clinical Practice, 2010, 14, 154-157.	1.2	7
548	Serotonin transporter gene variants and prediction of stress-induced risk for psychological distress. Genes, Brain and Behavior, 2011, 10, 536-541.	1.1	7
549	Bipolar disorder: "pure―versus mixed depression over a 1-year follow-up. International Journal of Psychiatry in Clinical Practice, 2012, 16, 113-120.	1.2	7
550	Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder. Journal of International Medical Research, 2013, 41, 809-815.	0.4	7
551	A Genetic Dissection of Antipsychotic Induced Movement Disorders. Current Medicinal Chemistry, 2013, 20, 312-330.	1.2	7
552	Genomewide interaction and enrichment analysis on antidepressant response. Psychological Medicine, 2014, 44, 753-765.	2.7	7
553	Association study ofCREB1polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. International Journal of Neuroscience, 2015, 125, 336-343.	0.8	7
554	Deiodinases, Organic Anion Transporter Polypeptide Polymorphisms, and Thyroid Hormones in Patients with Myocardial Infarction. Genetic Testing and Molecular Biomarkers, 2018, 22, 270-278.	0.3	7
555	The serotonin transporter and the activity regulated cytoskeletonâ€associated protein genes in antidepressant response and resistance: <scp>5â€HTTLPR</scp> and other variants. Human Psychopharmacology, 2018, 33, e2682.	0.7	7
556	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. Journal of Affective Disorders, 2021, 279, 722-729.	2.0	7
557	The association of childhood trauma, lifetime stressful events and general psychopathological symptoms in euthymic bipolar patients and healthy subjects. Journal of Affective Disorders, 2021, 289, 66-73.	2.0	7
558	No Association of a Set of Candidate Genes on Haloperidol Side Effects. PLoS ONE, 2012, 7, e44853.	1.1	7

#	Article	IF	CITATIONS
559	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. European Neuropsychopharmacology, 2022, 55, 112-157.	0.3	7
560	A genetic dissection of antipsychotic induced movement disorders. Current Medicinal Chemistry, 2013, 20, 312-30.	1.2	7
561	Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence. International Clinical Psychopharmacology, 2022, 37, 29-37.	0.9	7
562	Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. Journal of Clinical Medicine, 2022, 11, 3935.	1.0	7
563	S.17.05 Molecular genetics of bipolar disorders: Implication for psychotropic drugs. European Neuropsychopharmacology, 1997, 7, S112-S113.	0.3	6
564	Outcome of affective psychosis. , 1999, 10, 50-54.		6
565	Lack of association between tryptophan hydroxylase gene and psychotic symptomatology in schizophrenia. Schizophrenia Research, 1999, 40, 171-172.	1.1	6
566	Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia. Current Medicinal Chemistry, 2008, 15, 2472-2517.	1.2	6
567	No influence of FAT polymorphisms in response to aripiprazole. Journal of Human Genetics, 2010, 55, 32-36.	1.1	6
568	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 74-77.	2.5	6
569	Temperamental and Genetic Predictors of Suicide Attempt and Self-Mutilation. Neuropsychobiology, 2013, 68, 250-257.	0.9	6
570	Clozapine augmentation with amisulpride. Journal of Psychiatry and Neuroscience, 2014, 39, E38-E39.	1.4	6
571	Cenetic Variations within Metalloproteinases Impact on the Prophylaxis of Depressive Phases in Bipolar Patients. Neuropsychobiology, 2014, 69, 76-82.	0.9	6
572	Modulation of a number of genes on personality traits in a sample of healthy subjects. Neuroscience Letters, 2014, 566, 320-325.	1.0	6
573	Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders. Metabolic Brain Disease, 2016, 31, 183-189.	1.4	6
574	Nine differentially expressed genes from a post mortem study and their association with suicidal status in a sample of suicide completers, attempters and controls. Journal of Psychiatric Research, 2017, 91, 98-104.	1.5	6
575	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – Findings from a European multicenter study. Journal of Affective Disorders, 2018, 227, 254-259.	2.0	6
576	Antidepressant induced weight gain. BMJ: British Medical Journal, 2018, 361, k2151.	2.4	6

#	Article	IF	CITATIONS
577	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. Molecular Biology Reports, 2020, 47, 191-200.	1.0	6
578	Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure. Journal of Clinical Psychopharmacology, 2020, 40, 200-202.	0.7	6
579	Irritable Mood and Subthreshold Hypomanic Episodes Correlate with More Severe Major Depression. Neuropsychobiology, 2021, 80, 425-436.	0.9	6
580	Serotonin transporter gene (5-HTTLPR) and major psychoses. Molecular Psychiatry, 2002, 7, 95-99.	4.1	6
581	Imputed expression of schizophreniaâ€associated genes and cognitive measures in patients with schizophrenia. Molecular Genetics & Genomic Medicine, 2022, 10, e1942.	0.6	6
582	The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis. European Neuropsychopharmacology, 2022, 60, 55-75.	0.3	6
583	Low-dose buprenorphine detoxification in long term methadone addicts. Regulatory Peptides, 1994, 53, S289-S290.	1.9	5
584	DRD4 exon 3 variants are not associated with symptomatology of major psychoses in a German population. Neuroscience Letters, 2004, 368, 269-273.	1.0	5
585	Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre case–control study. Psychiatric Genetics, 2006, 16, 169-171.	0.6	5
586	No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. Neuropsychobiology, 2010, 62, 245-249.	0.9	5
587	DAOA Variants on Diagnosis and Response to Treatment in Patients with Major Depressive Disorder and Bipolar Disorder. Journal of International Medical Research, 2012, 40, 258-265.	0.4	5
588	Benefit of slow titration of paroxetine to treat depression in the elderly. Human Psychopharmacology, 2014, 29, 544-551.	0.7	5
589	Antagonist and partial agonist at the dopamine D2 receptors in drug-naÃ ⁻ ve and non-drug-naÃ ⁻ ve schizophrenia: a randomized, controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 579-588.	1.8	5
590	Maoa and Maob polymorphisms and personality traits in suicide attempters and healthy controls: a preliminary study. Psychiatry Research, 2017, 249, 212-217.	1.7	5
591	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. Journal of Molecular Neuroscience, 2018, 64, 273-286.	1.1	5
592	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. International Journal of Neuropsychopharmacology, 2020, 23, 571-577.	1.0	5
593	Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. World Journal of Biological Psychiatry, 2022, 23, 183-190.	1.3	5
594	<i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 231-240.	0.9	5

#	Article	IF	CITATIONS
595	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. European Neuropsychopharmacology, 2022, 56, 100-111.	0.3	5
596	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. Annals of Clinical Psychiatry, 2013, 25, 97-106.	0.6	5
597	Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features. International Clinical Psychopharmacology, 2022, 37, 166-172.	0.9	5
598	Title is missing!. Psychiatric Genetics, 2003, 13, 121-126.	0.6	4
599	DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes. International Journal of Psychiatry in Clinical Practice, 2011, 15, 303-310.	1.2	4
600	Impact of 5-HTTLPR Polymorphism on Alexithymia in Alcoholic Patients After Detoxification Treatment. Journal of Addiction Medicine, 2013, 7, 372-373.	1.4	4
601	Quetiapine Extended Release. Journal of Clinical Psychopharmacology, 2014, 34, 303-306.	0.7	4
602	<i>FKBP5</i> Gene Variants May Modulate Depressive Features in Bipolar Disorder. Neuropsychobiology, 2019, 78, 104-112.	0.9	4
603	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. Journal of Affective Disorders, 2021, 286, 149-157.	2.0	4
604	Epigenetic Basis of Psychiatric Disorders: A Narrative Review. CNS and Neurological Disorders - Drug Targets, 2022, 21, 302-315.	0.8	4
605	Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder. Psychiatry Investigation, 2008, 5, 102.	0.7	4
606	Analysis of depressive symptomatology in mood disorders. Depression and Anxiety, 1998, 8, 80-5.	2.0	4
607	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. Annals of Clinical Psychiatry, 2014, 26, 243-53.	0.6	4
608	Analysis of requirements and specifications for a monitoring system to support the self-management of dementia patients at home. , 2010, , .		3
609	P.3.c.055 Clozapine resistance: augmentation strategies. European Neuropsychopharmacology, 2011, 21, S500.	0.3	3
610	The challenge of uncovering the genetics of anxiety. Acta Psychiatrica Scandinavica, 2012, 125, 185-186.	2.2	3
611	A model to investigate SNPs' interaction in GWAS studies. Journal of Neural Transmission, 2015, 122, 145-153.	1.4	3
612	A molecular pathway analysis of the glutamatergic–monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. Journal of Neural Transmission, 2015, 122, 465-475.	1.4	3

#	Article	IF	CITATIONS
613	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	1.3	3
614	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. Journal of Molecular Neuroscience, 2018, 64, 62-74.	1.1	3
615	High occupational level is associated with poor response to the treatment of depression: A replication study. European Neuropsychopharmacology, 2019, 29, 349-355.	0.3	3
616	A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. Clinical Psychopharmacology and Neuroscience, 2021, 19, 160-165.	0.9	3
617	Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels. Journal of Clinical Psychopharmacology, 2021, 41, 694-696.	0.7	3
618	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. Journal of Affective Disorders, 2022, 296, 485-492.	2.0	3
619	Antidepressants: Indications, Contraindications, Interactions, and Side Effects. , 2020, , 1-38.		3
620	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110480.	2.5	3
621	Psychopharmacology: past, present and future. International Clinical Psychopharmacology, 2022, 37, 82-83.	0.9	3
622	Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants: A Pilot Study. Frontiers in Psychiatry, 2021, 12, 801738.	1.3	3
623	Reply to Comments by Dr Rico-Villademoros. Journal of Clinical Psychopharmacology, 2007, 27, 99.	0.7	2
624	No influence of <i>SLC6A3</i> 40 base VNTR polymorphism on the response to risperidone. International Journal of Psychiatry in Clinical Practice, 2010, 14, 228-232.	1.2	2
625	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. Psychopharmacology, 2011, 214, 719-728.	1.5	2
626	Pharmacogenomics of psychotropic drugs. Pharmacogenomics, 2011, 12, 1509-1510.	0.6	2
627	Social adjustment among treatment responder patients with mood disorders. Journal of Affective Disorders, 2013, 150, 961-966.	2.0	2
628	Potential Benefits of Slow Titration of Paroxetine Treatment in an Elderly Population. Journal of Clinical Psychopharmacology, 2013, 33, 565-569.	0.7	2
629	Persistent benefits of slow titration of paroxetine in a sixâ€month followâ€up. Human Psychopharmacology, 2015, 30, 329-333.	0.7	2
630	Brexpiprazole: a step forward for precision medicine in resistant depression. Expert Opinion on Pharmacotherapy, 2018, 19, 1817-1819.	0.9	2

1

#	Article	IF	CITATIONS
631	Is Pharmacogenetics Useful in Antidepressant Treatment?. Clinical Pharmacology and Therapeutics, 2019, 106, 916-918.	2.3	2
632	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2021, 19, 46-52.	0.9	2
633	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. American Journal of Medical Genetics Part A, 2000, 96, 136-140.	2.4	2
634	Pharmacogenetics of Antidepressant Response. , 2008, , 315-353.		2
635	The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach. Current Genomics, 2004, 5, 499-508.	0.7	2
636	The Neuropsychological Hypothesis of Antidepressant Drug Action Revisited. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1722-1739.	0.8	2
637	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2021, , .	1.0	2
638	A Genetic Dissection of Antipsychotic Induced Movement Disorders. Current Medicinal Chemistry, 2013, 20, 312-330.	1.2	2
639	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. Psychiatry Investigation, 2014, 11, 200.	0.7	2
640	The search for personalized antidepressant treatments: what have we learned and where are we going. Pharmacogenomics, 2020, 21, 1095-1100.	0.6	2
641	No interaction of GABA(A) alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. American Journal of Medical Genetics Part A, 1999, 88, 44-9.	2.4	2
642	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. American Journal of Medical Genetics Part A, 2000, 96, 84-7.	2.4	2
643	Precision medicine in mood disorders. , 2022, 1, .		2
644	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. Journal of Affective Disorders, 2022, 312, 225-234.	2.0	2
645	Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path. CNS and Neurological Disorders - Drug Targets, 2023, 22, 1267-1274.	0.8	2
646	Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder. International Clinical Psychopharmacology, 0, Publish Ahead of Print, .	0.9	2
647	The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls. Comprehensive Psychiatry, 2022, 117, 152335.	1.5	2

648 Genetics of Mood Disorders. , 2005, , 35-75.

#	Article	IF	CITATIONS
649	P.2.a.015 Weight gain and antidepressants: a comprehensive review and meta analysis. European Neuropsychopharmacology, 2008, 18, S301.	0.3	1
650	P.2.c.005 Meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. European Neuropsychopharmacology, 2008, 18, S327.	0.3	1
651	Pharmacogenomics of Depression. Advances in Biological Psychiatry, 2010, , 58-74.	0.2	1
652	Antidepressants, present and future. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1531.	2.5	1
653	The genetics of vascular incidents associated with second-generation antipsychotic administration. Expert Review of Clinical Pharmacology, 2014, 7, 75-90.	1.3	1
654	Low-activity alleles of the MAOA gene are associated with measures of hostility. Psychiatric Genetics, 2015, 25, 215.	0.6	1
655	P.1.a.006 CACNA1C gene and schizophrenia: A case-control and pharmacogenetic study. European Neuropsychopharmacology, 2015, 25, S162.	0.3	1
656	P.1.a.007 Four polymorphisms of SLC6A4 are novel predictors of SSRI/SNRI response in depressive disorder: sequencing analysis of SLC6A4. European Neuropsychopharmacology, 2015, 25, S162-S163.	0.3	1
657	Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs. , 2016, , 39-54.		1
658	22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders. Lancet Psychiatry,the, 2018, 5, 531-532.	3.7	1
659	Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment. Mindfulness, 2021, 12, 2059-2075.	1.6	1
660	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. Current Medicinal Chemistry, 2021, 28, 4296-4320.	1.2	1
661	"Dr. Zanardi and Colleagues Reply". Journal of Clinical Psychiatry, 2001, 62, 296.	1.1	1
662	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. American Journal of Medical Genetics Part A, 1999, 88, 294-7.	2.4	1
663	Outcome of affective psychosis. Depression and Anxiety, 1999, 10, 50-4.	2.0	1
664	Symptomatologic structure extraction of major psychosis and association with DRD4 exon 1 and 3 variants. Behavioural Pharmacology, 1995, 6, 69.	0.8	0
665	Positive association between bipolar affective disorder and tyrosine hydroxylase gene. Behavioural Pharmacology, 1995, 6, 124.	0.8	0
666	Psychopathology of dysthymia. European Psychiatry, 1998, 13, 258s-258s.	0.1	0

#	Article	IF	CITATIONS
667	S.03.05 Clinical pharmacogenetic studies in the treatment of depression. European Neuropsychopharmacology, 2006, 16, S169.	0.3	0
668	Major depressive disorders: depressive disorders. , 2006, , 45-73.		0
669	S.3.2 Genetic predictors of illness and treatment response. European Neuropsychopharmacology, 2007, 17, S69-S70.	0.3	0
670	P.1.a.006 Serotonin transporter: an example of gene influence on human behaviour. European Neuropsychopharmacology, 2008, 18, S205-S206.	0.3	0
671	P.1.a.007 A genetic assessment of antipsychotic and antidepressant cardiac iatrogenicity: focus on the proarrhythmic profile. European Neuropsychopharmacology, 2008, 18, S206.	0.3	0
672	Predictors of response to pharmacotherapy in mood and anxiety disorders: Commonalities, differences and indications. European Psychiatry, 2008, 23, S63.	0.1	0
673	Serotonin receptor 1a, 2a, 2c and CONT SNPs and personality traits in suicide attempters and controls. European Psychiatry, 2008, 23, S171-S172.	0.1	0
674	Serotonin transporter gene and adverse life events in adult ADHD. European Psychiatry, 2008, 23, S174.	0.1	0
675	Are Noradrenergic Antidepressants a Valuable Choice in the Treatment of Panic Disorder? A Review and Meta Analysis. European Psychiatry, 2009, 24, .	0.1	0
676	Corrigendum to: "TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study―[Eur Psychiatr 2008;23:390–5]. European Psychiatry, 2009, 24, 64-64.	0.1	0
677	METHODS FOR OBTAINING CLINICALLY USEFUL PHARMACOGENETIC PREDICTORS; AN EXAMPLE OF A DETAILED INVESTIGATION IN AN HALOPERIDOL TREATED SAMPLE. Schizophrenia Research, 2010, 117, 130.	1.1	0
678	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. European Psychiatry, 2011, 26, 1833-1833.	0.1	0
679	Clock genes and mood disorders: Which role?. European Psychiatry, 2011, 26, 2136-2136.	0.1	0
680	E.02.02 Pitfalls, problems and future. European Neuropsychopharmacology, 2011, 21, S233-S234.	0.3	0
681	P.2.c.026 Rapid versus slow titration of paroxetine antidepressant treatment in elderly population: an observational study. European Neuropsychopharmacology, 2011, 21, S397-S398.	0.3	0
682	P.2.e.025 Bipolar depression: quetiapine extended release effectiveness. European Neuropsychopharmacology, 2011, 21, S432.	0.3	0
683	Preface. Neuropsychobiology, 2011, 64, 127-128.	0.9	0
684	P.2.a.011 Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients. European Neuropsychopharmacology, 2012, 22, S230.	0.3	0

#	Article	IF	CITATIONS
685	P.3.c.044 Influence of ANKK1 and DRD2 gene polymorphisms in response to haloperidol. European Neuropsychopharmacology, 2012, 22, S342.	0.3	Ο
686	P.4.021 Genome-wide association analysis and pathway analysis in predicting antidepressant treatment response. European Neuropsychopharmacology, 2013, 23, S85.	0.3	0
687	P.1.a.021 A molecular pathway analysis of the genes in 22q11.2 provides information on the genetic structure of psychosis. European Neuropsychopharmacology, 2013, 23, S171-S172.	0.3	0
688	S.25.03 Pharmacogenetics of efficacy and treatment side effects in bipolar disorder. European Neuropsychopharmacology, 2013, 23, S148.	0.3	0
689	P.2.f.015 A prospective study of escitalopram in treatment resistant depression not responding to venlafaxine. European Neuropsychopharmacology, 2013, 23, S403-S404.	0.3	Ο
690	P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. European Neuropsychopharmacology, 2013, 23, S540-S541.	0.3	0
691	P.3.a.005 A deeper look onto schizophrenia mechanisms. Association with immunological related pathway. European Neuropsychopharmacology, 2013, 23, S424.	0.3	0
692	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. European Neuropsychopharmacology, 2013, 23, S168-S169.	0.3	0
693	P.2.f.025 Specificity profile of venlafaxine and sertraline in major depression: meta-regression of double-blind, randomized clinical trials. European Neuropsychopharmacology, 2013, 23, S409-S410.	0.3	0
694	Authors' reply to "Recommendations for conducting mindfulness based cognitive therapy trials― Psychiatry Research, 2013, 207, 232-233.	1.7	0
695	P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples. European Neuropsychopharmacology, 2013, 23, S403.	0.3	0
696	P.2.c.010 The inflammatory genetic background and genetically disruption of lithium related molecular pathways in bipolar disorder patients. European Neuropsychopharmacology, 2013, 23, S360.	0.3	0
697	P.2.b.026 Social adjustment among therapy responder patients with mood disorders. European Neuropsychopharmacology, 2013, 23, S334.	0.3	0
698	Pharmacogenetics of Antidepressant Drugs. , 2014, , 543-562.		0
699	P.3.015 Socio-demographic and clinical predictors of antidepressant remission and response in treatment resistant depression. European Neuropsychopharmacology, 2014, 24, S67-S68.	0.3	0
700	P.3.d.026 Pharmacogenetics of clozapine response and metabolic side effects: a comprehensive review and meta-analysis. European Neuropsychopharmacology, 2014, 24, S536-S537.	0.3	0
701	P.6.b.002 Oxidative stress and expression of alcohol related psychopathological symptoms in alcohol dependent subjects. European Neuropsychopharmacology, 2014, 24, S664.	0.3	0
702	P.3.018 Insomnia and somnolence induced by second-generation antidepressants during the treatment of major depression: a meta-analysis. European Neuropsychopharmacology, 2014, 24, S69-S70.	0.3	0

#	Article	IF	CITATIONS
703	P.1.014 PPP3CC: a new candidate gene in antidepressant response. European Neuropsychopharmacology, 2014, 24, S14-S15.	0.3	0
704	Highlights from the latest articles in suicideÂresearch. Personalized Medicine, 2014, 11, 255-258.	0.8	0
705	P1.a.023 Impact of a SNP in SIGMAR1 on major depression, bipolar disorder and treatment response. European Neuropsychopharmacology, 2015, 25, S170-S171.	0.3	0
706	P.1.a.034 Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease: a systematic review. European Neuropsychopharmacology, 2015, 25, S175-S176.	0.3	0
707	Gene-Environment Interaction Studies in Suicidal Behaviour. Advances in Biological Psychiatry, 0, , 63-74.	0.2	0
708	P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder. European Neuropsychopharmacology, 2015, 25, S159-S160.	0.3	0
709	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. European Neuropsychopharmacology, 2016, 26, S240-S241.	0.3	0
710	Epidemiology of psychopharmacological options in unipolar major depression in European tertiary psychiatric treatment centers. European Neuropsychopharmacology, 2016, 26, S417-S418.	0.3	0
711	Possible biomarkers modulating haloperidol efficacy and/or tolerability. Pharmacogenomics, 2016, 17, 507-529.	0.6	0
712	Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?. Evidence-Based Mental Health, 2016, 19, e25-e25.	2.2	0
713	Genes Involved In Neurodevelopment, Neuroplasticity And Bipolar Disorder: Cacna1c, Chrna1 And MAPK1. European Neuropsychopharmacology, 2017, 27, S451-S452.	0.3	0
714	Prescribing patterns of psychiatric drugs in major depressive disorder–ÂFindings from a large European multicenter, cross-sectional study. European Psychiatry, 2017, 41, S367-S367.	0.1	0
715	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. European Neuropsychopharmacology, 2017, 27, S583.	0.3	0
716	Potential genes behind the difference between bipolar I and bipolar II disorder. European Neuropsychopharmacology, 2017, 27, S836-S837.	0.3	0
717	Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder. European Neuropsychopharmacology, 2017, 27, S1057-S1058.	0.3	0
718	Highlights on Pharmacogenetics and Pharmacogenomics in Depression. , 2018, , 3-16.		0
719	F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S1166-S1167.	0.3	0
720	12 GENETIC UNDERPINNINGS OF SOCIABILITY. European Neuropsychopharmacology, 2019, 29, S65.	0.3	0

#	Article	IF	CITATIONS
721	M67 PSYCHIATRIC DISORDERS AND SLC6A4 GENE VARIANTS: POSSIBLE MODULATION OF ALCOHOL DEPENDENCE AND ALZHEIMER'S DISEASE. European Neuropsychopharmacology, 2019, 29, S202-S203.	0.3	Ο
722	WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S934-S935.	0.3	0
723	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis. European Neuropsychopharmacology, 2019, 29, S278-S279.	0.3	0
724	Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder. European Neuropsychopharmacology, 2019, 29, S378-S379.	0.3	0
725	M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S206-S207.	0.3	0
726	Attrition in treatment-resistant depression. International Clinical Psychopharmacology, 2019, 34, 161-169.	0.9	0
727	Precision psychiatry. Revista Brasileira De Psiquiatria, 2021, , .	0.9	0
728	Adaptación social y autoestima en pacientes con remisión de trastorno del estado de ánimo. European Psychiatry (Ed Española), 2000, 7, 26-32.	0.0	0
729	Dr. Benedetti and Colleagues Reply. American Journal of Psychiatry, 2000, 157, 1887-1888.	4.0	0
730	Pharmacogenetics of antipsychotics: focus on the glutamatergic system. Pharmacopsychiatry, 2011, 44,	1.7	0
731	Meet the Editorial Board:. Current Medicinal Chemistry, 2015, 22, 1169-1169.	1.2	0
732	The Role of Pharmacogenetics in Pharmacovigilance of Psychotropic Drugs. , 2016, , 121-146.		0
733	Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant, and Mood-Stabilizing Drugs. , 2016, , 111-117.		0
734	Evidence based criteria for the antidepressant choice. Dusunen Adam, 2017, , 1-5.	0.0	0
735	P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2021, 53, S646-S647.	0.3	0